Literature DB >> 12870926

Genetic algorithm applied to the selection of factors in principal component-artificial neural networks: application to QSAR study of calcium channel antagonist activity of 1,4-dihydropyridines (nifedipine analogous).

Bahram Hemmateenejad1, Morteza Akhond, Ramin Miri, Mojtaba Shamsipur.   

Abstract

A QSAR algorithm, principal component-genetic algorithm-artificial neural network (PC-GA-ANN), has been applied to a set of newly synthesized calcium channel blockers, which are of special interest because of their role in cardiac diseases. A data set of 124 1,4-dihydropyridines bearing different ester substituents at the C-3 and C-5 positions of the dihydropyridine ring and nitroimidazolyl, phenylimidazolyl, and methylsulfonylimidazolyl groups at the C-4 position with known Ca(2+) channel binding affinities was employed in this study. Ten different sets of descriptors (837 descriptors) were calculated for each molecule. The principal component analysis was used to compress the descriptor groups into principal components. The most significant descriptors of each set were selected and used as input for the ANN. The genetic algorithm (GA) was used for the selection of the best set of extracted principal components. A feed forward artificial neural network with a back-propagation of error algorithm was used to process the nonlinear relationship between the selected principal components and biological activity of the dihydropyridines. A comparison between PC-GA-ANN and routine PC-ANN shows that the first model yields better prediction ability.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12870926     DOI: 10.1021/ci025661p

Source DB:  PubMed          Journal:  J Chem Inf Comput Sci        ISSN: 0095-2338


  9 in total

1.  Different effects of dihydropyridine calcium channel antagonists on CYP3A4 enzyme of human liver microsomes.

Authors:  Zongling Xia; Mingli Wang; Sulan Zou; Rong Chen
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-12-13       Impact factor: 2.441

Review 2.  Genetic algorithm optimization in drug design QSAR: Bayesian-regularized genetic neural networks (BRGNN) and genetic algorithm-optimized support vectors machines (GA-SVM).

Authors:  Michael Fernandez; Julio Caballero; Leyden Fernandez; Akinori Sarai
Journal:  Mol Divers       Date:  2010-03-20       Impact factor: 2.943

3.  Genetic neural network modeling of the selective inhibition of the intermediate-conductance Ca2+ -activated K+ channel by some triarylmethanes using topological charge indexes descriptors.

Authors:  Julio Caballero; Miguel Garriga; Michael Fernández
Journal:  J Comput Aided Mol Des       Date:  2005-12-23       Impact factor: 3.686

4.  Novel approach to evolutionary neural network based descriptor selection and QSAR model development.

Authors:  Zeljko Debeljak; Viktor Marohnić; Goran Srecnik; Marica Medić-Sarić
Journal:  J Comput Aided Mol Des       Date:  2006-04-11       Impact factor: 3.686

5.  Multi-space classification for predicting GPCR-ligands.

Authors:  Alireza Givehchi; Gisbert Schneider
Journal:  Mol Divers       Date:  2005       Impact factor: 2.943

6.  Interaction Site Preference between Carbon Nanotube and Nifedipine: A Combined Density Functional Theory and Classical Molecular Dynamics Study.

Authors:  Huichun Liu; Yuxiang Bu; Yunjie Mi; Yixuan Wang
Journal:  Theochem       Date:  2009-05-15

7.  Deep learning and virtual drug screening.

Authors:  Kristy A Carpenter; David S Cohen; Juliet T Jarrell; Xudong Huang
Journal:  Future Med Chem       Date:  2018-10-05       Impact factor: 3.808

8.  Toward the prediction of FBPase inhibitory activity using chemoinformatic methods.

Authors:  Ming Hao; Shuwei Zhang; Jieshan Qiu
Journal:  Int J Mol Sci       Date:  2012-06-07       Impact factor: 6.208

Review 9.  Machine Learning Based Toxicity Prediction: From Chemical Structural Description to Transcriptome Analysis.

Authors:  Yunyi Wu; Guanyu Wang
Journal:  Int J Mol Sci       Date:  2018-08-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.